Financial Performance - The company's operating revenue for 2021 was ¥891,835,182.38, representing a 20.32% increase compared to ¥741,237,325.38 in 2020[19] - The net profit attributable to shareholders for 2021 was ¥134,848,862.26, which is a 27.04% increase from ¥106,146,369.35 in 2020[19] - The net profit after deducting non-recurring gains and losses was ¥131,494,576.68, up 35.13% from ¥97,309,903.36 in 2020[19] - The net cash flow from operating activities increased by 29.99% to ¥212,536,478.83 from ¥163,505,165.65 in 2020[19] - The total assets at the end of 2021 were ¥2,111,282,192.35, an increase of 11.79% from ¥1,888,641,664.49 at the end of 2020[19] - The net assets attributable to shareholders increased by 9.25% to ¥1,742,292,532.40 from ¥1,594,720,660.84 at the end of 2020[19] - The basic earnings per share for 2021 was ¥0.2680, a 27.07% increase from ¥0.2109 in 2020[19] - The weighted average return on equity for 2021 was 8.06%, up from 6.71% in 2020[19] Revenue Breakdown - The company's total revenue for Q1 was ¥235.39 million, Q2 was ¥207.70 million, Q3 was ¥216.83 million, and Q4 was ¥231.92 million, showing a stable performance throughout the year[23] - The net profit attributable to shareholders for Q1 was ¥45.73 million, Q2 was ¥24.90 million, Q3 was ¥42.86 million, and Q4 was ¥21.36 million, indicating fluctuations in profitability[23] - The net cash flow from operating activities for Q1 was ¥70.89 million, Q2 was ¥44.82 million, Q3 was ¥63.16 million, and Q4 was ¥33.67 million, reflecting a strong cash generation capability in the first half of the year[23] Product and Market Development - The company is engaged in the pharmaceutical manufacturing industry, focusing on traditional Chinese medicine, chemical drugs, and medical preparations, with plans to expand into the health care sector[31] - The company has introduced several key products, including Qumotang Oral Liquid and Ginkgo Leaf Capsules, targeting various health issues such as digestive disorders and cardiovascular diseases[31] - The pharmaceutical industry is experiencing rapid growth due to factors such as increased disposable income, healthcare reforms, and an aging population, which are expected to drive demand for medical products[29] - The company is adapting to significant policy changes in the pharmaceutical sector, including the national volume-based procurement policy aimed at promoting innovation and high-quality development[30] - The company has maintained a focus on research and development to enhance its product offerings and meet evolving market demands[31] Strategic Initiatives - The company has established a marketing system that includes hospital, grassroots, chain, distribution, and e-commerce sales channels to enhance brand promotion[38] - The company is expanding into the health and medical care sector with the establishment of the Hunan Hansen Health Industry Park[37] - The company has implemented a procurement management system to control costs and ensure quality, with a focus on supplier evaluation and market price tracking[35] - The company is committed to continuous product development and market support, aiming for sustainable profit growth[37] Governance and Compliance - The company emphasizes the importance of information disclosure and investor relations management, ensuring timely and accurate information dissemination to all investors[102] - The company maintains a fully independent business system, with no shared financial or operational resources with its controlling shareholders[104] - The company has established a dedicated investor relations section on its website to facilitate communication with investors[103] - The company has a clear structure for its board of directors, with all members fulfilling their duties in accordance with relevant laws and regulations[101] - The company has a dedicated internal audit department that supervises daily operations and major related transactions[103] Risk Management - The management has outlined potential risks and countermeasures in the future development outlook section of the report[4] - The company faces risks related to policy changes in the pharmaceutical industry, with significant impacts from national regulations and healthcare reforms[93] - The company plans to continuously monitor the pandemic situation and adjust product sales strategies to minimize adverse impacts[96] Employee and Corporate Culture - The company has invested in employee training and development, establishing a performance management system to motivate staff and improve overall quality[44] - The company is focused on enhancing corporate culture and talent management to improve employee engagement and retention[92] - The company has maintained a strong focus on employee rights, providing a safe working environment and comprehensive social insurance[141] Financial Management - The company has implemented a strict remuneration system for its directors and senior management based on their roles and performance[116] - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to RMB 3.39 million[117] - The company has established a comprehensive internal control system in accordance with relevant laws and regulations, covering various management aspects[133] Investment and Acquisitions - The company has established a new subsidiary, Hunan Shanshui Kangcheng Real Estate Development Co., Ltd., with a registered capital of 50 million yuan, fully owned by Hunan Hansen Health Industry Co., Ltd.[152] - The company acquired 80% of Yunnan Yongzitang Pharmaceutical Co., Ltd. for CNY 282 million using over-raised funds[79] - The company plans to increase its investment in its wholly-owned subsidiary by RMB 138 million to support the health industry project[178] Environmental and Social Responsibility - The company has implemented measures to reduce carbon emissions, including promoting green office practices and resource recycling[140] - The company has reported no environmental penalties during the reporting period, demonstrating its commitment to environmental protection[139] - The company emphasizes environmental protection and sustainable development, continuously improving its environmental management to meet industry requirements[142]

Financial Performance - The company's revenue for Q3 2021 was ¥216,830,821.90, representing a 3.17% increase compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2021 was ¥42,856,985.53, a 35.95% increase year-over-year[4] - The basic earnings per share for Q3 2021 was ¥0.0852, reflecting a 36.10% increase compared to the same period last year[4] - Total operating revenue for Q3 2021 reached CNY 659.92 million, a 26.4% increase from CNY 521.90 million in the same period last year[23] - Net profit for Q3 2021 was CNY 113.49 million, representing a 33.9% increase compared to CNY 84.75 million in Q3 2020[24] - Earnings per share for Q3 2021 were CNY 0.2255, compared to CNY 0.1684 in the same quarter last year, reflecting a 34% increase[24] - The total comprehensive income for Q3 2021 increased by 43.37%, amounting to an increase of ¥36,691,119.89 compared to the previous year[11] - The company reported a total comprehensive income of CNY 121.30 million for Q3 2021, compared to CNY 84.61 million in Q3 2020, marking a 43.3% increase[24] Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥2,043,914,429.74, an increase of 8.22% from the end of the previous year[4] - The company's current assets totaled CNY 575,472,832.57, compared to CNY 527,456,165.16 at the end of 2020, indicating an increase of about 9.1%[20] - The total non-current assets reached CNY 1,468,441,597.17, compared to CNY 1,361,185,499.33 at the end of 2020, which is an increase of about 7.9%[20] - Total liabilities as of Q3 2021 were CNY 327.90 million, an increase from CNY 293.92 million in the same period last year[23] - The company’s total liabilities decreased by 65.11% in contract liabilities, reflecting a reduction in pre-received customer payments[8] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥178,868,988.40, showing a 50.56% increase[4] - The company experienced a 50.56% increase in net cash flow from operating activities, primarily due to increased cash received from sales[11] - Cash flow from operating activities for Q3 2021 was CNY 178.87 million, an increase of 50.6% from CNY 118.80 million in Q3 2020[26] - The net cash flow from investing activities was -150,779,901.61, compared to -19,680,203.90 in the previous year, indicating a significant increase in cash outflows for investments[27] - Cash inflows from financing activities totaled 130,153,195.20, up from 110,191,243.32 year-over-year, reflecting an increase in borrowings[27] - The net cash flow from financing activities was -5,603,689.48, an improvement from -93,931,660.42 in the same period last year, showing reduced cash outflows for debt repayment and dividends[27] - The total cash and cash equivalents at the end of the period amounted to 126,046,267.58, compared to 121,797,903.72 at the end of the previous year, indicating a slight increase[27] Investments and Expenses - The company reported a 43.40% increase in investment income, amounting to an increase of ¥16,481,080.16 compared to the previous year[10] - Research and development expenses for Q3 2021 amounted to CNY 26.34 million, up 19.5% from CNY 21.95 million in the previous year[23] - Total operating costs for Q3 2021 were CNY 593.90 million, up 25.3% from CNY 474.33 million in Q3 2020[23] Compliance and Governance - The company has acknowledged the need for corrective measures following regulatory scrutiny, emphasizing its commitment to compliance and transparency[16] - The company held a board meeting to address prior accounting errors, ensuring adherence to accounting standards and improving financial reporting accuracy[17] - The third quarter report was not audited, which may affect the reliability of the financial data presented[30] Other Comprehensive Income - The company’s other comprehensive income increased by 90.21%, amounting to an increase of ¥7,803,735.27 compared to the previous year[9] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[23]

证券代码：002412 证券简称：汉森制药 公告编号：2021-045 湖南汉森制药股份有限公司 关于参加 2021 年湖南辖区上市公司投资者 网上集体接待日活动的公告 本公司及全体董事保证公告内容真实、准确和完整，不存在虚假记载、误导性 陈述或者重大遗漏。 为进一步加强与广大投资者的沟通交流，湖南汉森制药股份有限公司（以下 简称"公司"）将参加由中国证券监督管理委员会湖南证监局主办、湖南省上市 公司协会与深圳市全景网络有限公司协办的"湖南辖区上市公司投资者网上集体 接待日" 活动，现将有关事项公告如下： 本次网上集体接待日活动将采取网络远程的方式举行，投资者可以登录"全 景·路演天下"网站（http://rs.p5w.net），参与本次投资者网上集体接待日活动， 活动时间为 2021 年 09 月 24 日（星期五）下午 15：00 至 17：00。 届时公司董事会秘书等相关人员将通过网络在线问答互动的形式，就投资者 关心的问题进行沟通与交流。 欢迎广大投资者积极参与。 | --- | --- | --- | |-------|-------|-------------------------------| ...

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 443,087,312.44, representing a 42.14% increase compared to CNY 311,730,353.40 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was CNY 70,635,880.51, up 32.70% from CNY 53,230,273.07 in the previous year[18]. - The net cash flow from operating activities reached CNY 115,705,962.98, a significant increase of 206.65% compared to CNY 37,731,814.71 in the same period last year[18]. - The total assets at the end of the reporting period were CNY 2,037,929,328.35, reflecting a 7.90% increase from CNY 1,888,641,664.49 at the end of the previous year[18]. - The net assets attributable to shareholders of the listed company increased by 4.38% to CNY 1,664,522,081.50 from CNY 1,594,720,660.84 at the end of the previous year[18]. - The basic earnings per share for the first half of 2021 were CNY 0.1404, a 32.70% increase from CNY 0.1058 in the same period last year[18]. - Operating profit reached 79.84 million yuan, up 23.38% compared to the same period last year[30]. - The company reported a total of CNY 1,364,669.87 in non-recurring gains and losses during the reporting period[22]. Cash Flow and Financial Management - The company reported a significant increase in cash and cash equivalents, which rose by 354.43% to ¥78,270,772.81, reflecting improved operational cash flow[36]. - The company's cash and cash equivalents increased by 75.58% to ¥181.83 million compared to the beginning of the year[46]. - The cash flow from operating activities generated a net amount of CNY 115,705,962.98, significantly higher than CNY 37,731,814.71 in the previous year[132]. - The company received CNY 100,000,000.00 in borrowings during the first half of 2021, compared to CNY 60,000,000.00 in the same period of 2020[132]. - The company has maintained a cash flow that is relatively abundant, allowing for normal production and operation without significant project expenditures[84]. Market and Product Development - The company is gradually expanding into the health industry and medical care sectors[26]. - The company’s main products include traditional Chinese medicine, chemical drugs, and medical preparations, with a focus on various therapeutic functions[26][27][28][29]. - The company plans to diversify its product offerings, which is expected to support sustained profit growth in the future[36]. - The company is focused on enhancing its health industry park project, reflecting its strategic growth initiatives[94]. - The company plans to continue expanding its market presence and investing in new product development in the upcoming quarters[145]. Risks and Compliance - The company faces risks related to policy changes in the pharmaceutical industry, with significant reliance on its leading product, Si Mo Tang Oral Liquid, which accounts for over 50% of revenue[54]. - The company is actively taking measures to mitigate risks, including optimizing product structure and enhancing market development efforts[57]. - The company plans to strengthen product quality control and adhere to environmental regulations to manage production-related risks[55]. - The company has not engaged in targeted poverty alleviation or rural revitalization efforts during the reporting period, nor are there any subsequent plans[66]. - The company has committed to ensuring the legality and fairness of related party transactions, with strict adherence to relevant laws and regulations[70]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 23,678[100]. - The largest shareholder, Xinjiang Hansen Equity Investment Management Partnership, holds 42.13% of the shares, totaling 212,006,189 shares[100]. - The total number of shares is 503,200,000, with 1.90% being limited sale condition shares and 98.10% being unrestricted sale condition shares[98]. - The number of shares pledged by the largest shareholder is 135,175,000[100]. - The company has not experienced any changes in its controlling shareholder during the reporting period[103]. Accounting and Financial Reporting - The financial report was approved on August 26, 2021, by the 10th meeting of the 5th Board of Directors[151]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring the financial statements reflect the true financial condition as of June 30, 2021[156]. - The company’s financial statements are prepared based on the accrual basis of accounting, reflecting actual transactions and events[153]. - The company will reassess control definitions if relevant facts and circumstances change, impacting the consolidation scope[166]. - The company applies the equity method for investments in joint ventures, recognizing its share of assets and liabilities[169]. Inventory and Asset Management - Inventory levels increased to CNY 88,583,527.48 from CNY 84,428,766.98, showing a growth of approximately 4.79%[113]. - The company recognizes inventory impairment when the net realizable value is lower than the cost, with provisions made based on the difference for each inventory item[187]. - Non-current assets totaled CNY 1,440,270,094.77, an increase from CNY 1,361,185,499.33, indicating a growth of approximately 5.81%[114]. - The company has not engaged in any asset or equity acquisitions or sales during the reporting period[80]. Research and Development - Research and development expenses increased by 34.06% to ¥17,791,098.85, primarily due to higher costs associated with the consistency evaluation of iodinated contrast agents[35]. - Research and development expenses for the first half of 2021 were CNY 17.79 million, up 33.93% from CNY 13.27 million in the first half of 2020[121]. Other Financial Metrics - The company's financial expenses decreased by 22.14% to ¥2,548,339.80, indicating improved financial management[35]. - The gross profit margin for the pharmaceutical industry was 72.62%, an increase of 1.40% compared to the previous year[40]. - The company reported a total comprehensive income of CNY 68,480,106.67, compared to CNY 49,994,258.63 in the same period last year, reflecting a growth of 37.0%[128].

Financial Performance - The company's operating revenue for 2020 was ¥741,237,325.38, a decrease of 16.48% compared to ¥887,490,963.28 in 2019[16] - The net profit attributable to shareholders for 2020 was ¥106,146,369.35, down 34.63% from ¥162,377,707.21 in 2019[16] - The net profit after deducting non-recurring gains and losses was ¥97,309,903.36, a decline of 36.95% from ¥154,338,124.68 in 2019[16] - The basic earnings per share for 2020 was ¥0.2109, a decrease of 34.65% compared to ¥0.3227 in 2019[16] - The total non-operating income and expenses, excluding the aforementioned items, resulted in a loss of ¥405,941.47 in 2020, compared to a profit of ¥1,680,205.33 in 2019[23] - The total non-recurring profit and loss for the company in 2020 was ¥8,836,465.99, slightly up from ¥8,039,582.53 in 2019[23] - The company's revenue for the pharmaceutical industry was approximately ¥739.97 million, a decrease of 16.50% compared to the same period last year[49] - The gross profit margin for the pharmaceutical industry was 70.27%, down 3.51% year-on-year[49] Assets and Liabilities - The total assets at the end of 2020 were ¥1,888,641,664.49, an increase of 0.30% from ¥1,882,905,804.71 at the end of 2019[16] - The net assets attributable to shareholders at the end of 2020 were ¥1,594,720,660.84, up 4.23% from ¥1,529,977,688.84 at the end of 2019[16] - The company's deferred income tax assets increased by 35.43%, reflecting an increase in government subsidies related to assets[34] - Long-term equity investments rose to ¥628.39 million, representing 33.27% of total assets, an increase of 2.54% from the previous year[64] - Other receivables increased dramatically by 1992.11% to ¥35.15 million, primarily due to a land guarantee payment of ¥23.60 million[64] Cash Flow - The net cash flow from operating activities for 2020 was ¥163,505,165.65, a decrease of 2.55% from ¥167,788,107.51 in 2019[16] - Operating cash inflow for 2020 was ¥928.73 million, a decrease of 4.88% compared to ¥976.33 million in 2019[60] - Investment cash inflow increased by 74.60% to ¥35.75 million, while investment cash outflow surged by 103.83% to ¥154.32 million, resulting in a net cash flow from investment activities of -¥118.57 million, a decline of 114.67%[60][61] - Net increase in cash and cash equivalents was -¥13.05 million, a significant drop of 138.50% from an increase of ¥33.89 million in 2019[61] Business Operations - The company's main business includes the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations, with a gradual expansion into the health and medical care sectors[26] - The product "Si Mo Tang Oral Liquid" is the only compound gastrointestinal motility traditional Chinese medicine product in the market, showing significant therapeutic effects, especially in post-operative recovery[30] - In 2020, the company faced a decline in sales volume due to the pandemic, leading to a decrease in operating income and net profit[30] - The marketing strategy includes a diversified approach with hospital promotion, grassroots promotion, chain promotion, distribution promotion, and controlled marketing[30] - The company has established a procurement management system to ensure quality and cost-effectiveness in raw material sourcing, adapting to market changes[30] Research and Development - Research and development expenses amounted to ¥31.63 million, representing 4.27% of total revenue, an increase from 3.79% in the previous year[59] - The number of R&D personnel increased by 32.28% to 209, accounting for 13.83% of the total workforce[59] - The company achieved a significant increase in the capitalized amount of R&D expenses by 139.74% compared to the previous year[59] Strategic Initiatives - The company plans to focus on innovation-driven development, launching new specifications and formulations for its key products, and enhancing production quality control technology[85] - The company aims to achieve a stable growth in performance in 2021 while ensuring the "four safety" principles, emphasizing quality improvement and operational efficiency[86] - The company intends to extend its business into health and medical care sectors, including the construction of traditional Chinese medicine GAP bases and elderly care services[85] - The company aims to rank among the top 50 pharmaceutical companies in China, focusing on product advantages and core competitiveness[85] Governance and Compliance - The company has established a sound internal control system to protect the rights of shareholders and creditors, ensuring compliance with relevant laws and regulations[131] - The company emphasizes employee rights protection, providing a good working environment and signing labor contracts with all employees[131] - The company has implemented a performance evaluation system and conducts regular health check-ups for employees[131] - The company has established a robust internal audit system to supervise daily operations and major transactions[181] Shareholder Information - The total share capital is 503,200,000 shares, with a cash dividend of RMB 0.75 per 10 shares for the 2019 annual equity distribution[136] - The company has not distributed any cash dividends in 2020 and plans to roll over the undistributed profits to meet future operational funding needs[98] - The company has committed to not distributing cash dividends or bonus shares for the current fiscal year[99] Risk Management - The company has indicated potential risks in its future development outlook, which investors should be aware of[4] - The company faces risks from policy changes in the pharmaceutical industry, including stricter drug approval and quality supervision regulations[88] - The company is committed to improving product quality control and adhering to safety and environmental standards to mitigate production risks[91]

Financial Performance - The company's operating revenue for Q1 2021 was CNY 235,387,600.31, representing a 35.01% increase compared to CNY 174,351,660.96 in the same period last year[7]. - Net profit attributable to shareholders was CNY 45,731,537.24, up 23.79% from CNY 36,943,574.88 year-on-year[7]. - Basic earnings per share were CNY 0.0909, reflecting a 23.84% increase from CNY 0.0734 in the same quarter last year[7]. - The company's operating profit for Q1 2021 was CNY 51.78 million, an increase of 20.3% from CNY 43.02 million in the same period last year[44]. - The total profit for Q1 2021 was CNY 51.79 million, an increase of 21.6% from CNY 42.54 million in Q1 2020[44]. - The total comprehensive income for Q1 2021 was CNY 41.99 million, a decrease of 15.5% from CNY 49.69 million in Q1 2020[42]. Cash Flow - The net cash flow from operating activities reached CNY 70,886,845.47, a significant increase of 1,325.96% compared to a negative cash flow of CNY 5,782,168.59 in the previous year[7]. - The cash flow from operating activities for Q1 2021 was CNY 70.89 million, a significant improvement compared to a negative cash flow of CNY 5.78 million in the same period last year[49]. - The net increase in cash and cash equivalents was CNY 13,213,916.83, a growth of 76.77%, attributed to the increase in net cash flow from operating activities[17]. - The total cash inflow from operating activities was CNY 191,560,827.13, compared to CNY 155,880,859.60 in the previous year, marking an increase of approximately 22.9%[51]. - The net cash flow from investing activities was -CNY 14,063,709.06, compared to -CNY 405,308.11 in the previous year, showing increased investment outflows[53]. - The net cash flow from financing activities was -CNY 31,612,220.24, contrasting with a positive net cash flow of CNY 28,495,809.77 in the same period last year[53]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,921,371,947.38, a 1.73% increase from CNY 1,888,641,664.49 at the end of the previous year[7]. - The company's total liabilities decreased to CNY 304,748,285.27 from CNY 310,340,450.87, a reduction of approximately 1.9%[37]. - The equity attributable to shareholders increased to CNY 1,668,458,110.60 from CNY 1,629,570,165.96, indicating a growth of about 2.4%[37]. - Cash and cash equivalents increased to CNY 89,794,057.91 from CNY 71,947,021.43, marking a rise of approximately 24.9%[34]. - Accounts receivable rose to CNY 204,273,523.74 from CNY 166,163,659.43, reflecting an increase of about 22.9%[34]. - The ending balance of other current assets decreased by CNY 22,307,819.74, a decline of 91.85%, primarily due to the offset of prepaid VAT by the parent company during the reporting period[15]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,411[11]. - The largest shareholder, Xinjiang Hansen Equity Investment Management Partnership, holds 42.13% of the shares, amounting to 212,006,189 shares[11]. - The company did not engage in any repurchase transactions during the reporting period[12]. Expenses and Costs - Operating costs rose by CNY 16,819,782.53, a growth of 36.90%, corresponding to the increase in sales revenue[15]. - Sales expenses increased by CNY 31,580,411.32, a growth of 40.96%, mainly due to increased sales activities during the reporting period[16]. - Research and development expenses for Q1 2021 amounted to CNY 5.22 million, up from CNY 4.37 million in Q1 2020, indicating a focus on innovation[44]. - The company reported a research and development expense of CNY 6,396,211.92, compared to CNY 5,184,895.94 in the previous year, reflecting an increase of approximately 23.3%[40]. Other Income and Gains - The company reported non-recurring gains and losses totaling CNY 788,560.30 for the reporting period[8]. - Other income increased by CNY 263,173.12, a growth of 41.37%, primarily due to a government subsidy received for the smart manufacturing system[16]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[44].

Financial Performance - Net profit attributable to shareholders was CNY 31,523,068.60, an increase of 0.37% year-on-year[7]. - Operating revenue for the reporting period was CNY 210,165,433.40, representing a growth of 4.21% compared to the same period last year[7]. - Basic earnings per share were CNY 0.0626, reflecting a slight increase of 0.32% compared to the previous year[7]. - The weighted average return on equity was 2.01%, a decrease of 0.14% from the previous year[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 24,070,607.76, a decrease of 18.44% year-on-year[7]. - The total profit for the third quarter was CNY 30,897,974.75, compared to CNY 37,469,661.10 in the same quarter last year, indicating a decline of approximately 17.6%[44]. - The net profit for the third quarter was CNY 31,523,068.60, slightly up from CNY 31,405,807.94 year-over-year, indicating a stable performance[44]. - The comprehensive income totalled CNY 27,945,659.86, down from CNY 28,676,195.09 in the previous year, showing a decrease of about 2.5%[45]. - The total profit for the third quarter was CNY 95,303,572.66, down 23.5% from CNY 124,501,789.52 year-over-year[52]. Cash Flow - The net cash flow from operating activities was CNY 81,067,442.42, an increase of 19.66% year-on-year[7]. - The net cash flow from operating activities was 118,799,257.13 CNY, a decrease of 1.04% compared to 121,055,667.96 CNY in the previous period[62]. - The total cash inflow from investment activities was 10,216,295.00 CNY, while cash outflow was 29,896,498.90 CNY, resulting in a net cash flow of -19,680,203.90 CNY, an improvement from -41,553,427.00 CNY in the previous period[63]. - The net cash flow from financing activities decreased by CNY 46,579,960.34, a decline of 98.37%, mainly due to cash dividends paid during the period[15]. - The net cash flow from financing activities was -93,931,660.42 CNY, compared to -47,351,700.08 CNY in the previous period, indicating increased cash outflows for debt repayment and interest payments[63]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,838,835,275.85, a decrease of 2.34% compared to the end of the previous year[7]. - The company's current assets totaled CNY 529,075,303.09, down from CNY 593,861,751.70 at the end of 2019, indicating a decline of approximately 10.9%[33]. - The total liabilities of the company were not explicitly stated, but the decrease in current liabilities can be inferred from the reduction in short-term borrowings and accounts payable[34]. - Total liabilities amounted to CNY 352,928,115.87, with current liabilities at CNY 336,524,092.92 and non-current liabilities at CNY 16,404,022.95[72]. - The total equity attributable to shareholders reached CNY 1,529,977,688.84, with retained earnings of CNY 733,653,864.39[72]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,558[11]. - The largest shareholder, Xinjiang Hansen Equity Investment Management Partnership, holds 42.13% of the shares[11]. Investments and Expenses - The company reported non-recurring gains of CNY 8,097,431.74 during the reporting period[8]. - Research and development expenses increased to CNY 8,680,853.06 from CNY 6,294,832.50[43]. - Research and development expenses increased to CNY 21,951,717.63, up 10.2% from CNY 19,926,110.91 year-over-year[52]. - The company reported an increase in investment income to CNY 12,729,073.10 from CNY 10,708,645.42, representing a growth of about 18.8% year-over-year[48]. Other Financial Metrics - Other receivables increased by CNY 10,042,553.08, a growth of 597.77%, mainly due to loans to Changsha Sanyin Real Estate Development Co., Ltd.[15]. - Other current assets decreased by CNY 25,897,445.17, a decline of 65.31%, primarily due to reduced financial product purchases by Yunnan Yongzitang Pharmaceutical Co., Ltd.[15]. - Financial expenses decreased by CNY 3,022,500.64, a decline of 37.48%, due to reduced bank loans and corresponding interest expenses.[15]. - The company experienced a credit impairment loss of CNY 1,042,850.64, compared to a gain of CNY 583,998.45 in the previous year[52].

证券代码：002412 证券简称：汉森制药 公告编号：2020-049 湖南汉森制药股份有限公司 关于参加湖南辖区上市公司 2020 年度投资者 网上集体接待日活动的公告 本公司及全体董事保证公告内容真实、准确和完整，不存在虚假记载、误 导性陈述或者重大遗漏。 为进一步加强与广大投资者的沟通交流，湖南汉森制药股份有限公司（以下 简称"公司"）将参加由中国证券监督管理委员会湖南监管局、湖南省上市公司 协会与深圳市全景网络有限公司联合举办的"湖南辖区上市公司 2020 年度投资 者网上集体接待日"活动，现将有关事项公告如下： 本次集体接待日活动将采取网络远程的方式举行，投资者可以登录"全景·路 演天下"网站（http://rs.p5w.net），参与本次网上投资者接待日活动。活动时间 为 2020 年 9 月 11 日（星期五）下午 15：00 至 17：00。 届时公司董事会秘书、证券事务代表等相关人员将通过网络在线问答互动的 形式，与投资者进行沟通和交流。 欢迎广大投资者积极参与。 湖南汉森制药股份有限公司 董事会 2020 年 9 月 9 日 - 1 - ...

Financial Performance - The company's operating revenue for the first half of 2020 was ¥311,730,353.40, a decrease of 25.69% compared to ¥419,493,223.72 in the same period last year[17]. - The net profit attributable to shareholders was ¥53,230,273.07, down 25.97% from ¥71,900,694.70 in the previous year[17]. - The net profit after deducting non-recurring gains and losses was ¥52,585,302.17, a decrease of 20.62% compared to ¥66,248,160.66 in the same period last year[17]. - The net cash flow from operating activities was ¥37,731,814.71, down 29.22% from ¥53,307,369.59 in the previous year[17]. - The basic earnings per share were ¥0.1058, a decline of 25.96% from ¥0.1429 in the same period last year[17]. - The company reported a significant increase in cash flow from investment activities, with a net cash flow of -¥7,340,218.97, reflecting a 79.74% increase compared to the previous period[43]. - The total comprehensive income for the first half of 2020 was CNY 49,994,258.63, down 23.2% from CNY 65,140,013.47 in the same period of 2019[144]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,813,897,322.65, a decrease of 3.66% from ¥1,882,905,804.71 at the end of the previous year[17]. - Total liabilities decreased from ¥352,928,115.87 to ¥264,999,812.25, a decline of about 25%[131]. - Total equity increased from ¥1,529,977,688.84 to ¥1,548,897,510.40, reflecting an increase of approximately 1.2%[132]. - Cash and cash equivalents decreased from ¥116,610,510.91 to ¥85,847,084.20, representing a decrease of about 26.4%[129]. - Accounts receivable decreased from ¥274,774,541.22 to ¥233,350,999.34, a reduction of approximately 15.1%[129]. - Inventory increased from ¥85,422,380.74 to ¥96,175,337.77, an increase of about 12.8%[129]. Operational Strategies - The company operates in the pharmaceutical manufacturing industry, focusing on the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations, with gradual expansion into the health and medical care sectors[25]. - The company employs a market-oriented production model, adjusting production plans monthly based on sales forecasts and inventory levels to ensure stable product supply[28]. - The company’s procurement strategy involves strict quality control and cost management, ensuring that raw materials are sourced from qualified suppliers while monitoring market trends[28]. - The marketing strategy includes a diversified approach with hospital promotion, grassroots promotion, and distribution channels, adapting to industry changes and enhancing sales effectiveness[29]. - The company plans to continue expanding into the health and medical care sectors, aiming for diversified growth[33]. Product Performance - The company reported a 114.27% year-on-year increase in revenue for the Tianma Xingnao capsule, which has been included in chronic disease directories in certain provinces[29]. - The company’s main product, Si Mo Tang oral solution, is the only compound gastrointestinal motility traditional Chinese medicine product on the market, showing significant therapeutic effects, especially in post-operative gastrointestinal recovery[29]. - Revenue from Si Mo Tang oral liquid decreased by 38.67% year-on-year, mainly due to the impact of the pandemic[49]. - Revenue from Ginkgo Biloba capsules decreased by 35.74% year-on-year, also primarily due to pandemic-related sales impacts[49]. Risk Management - The company faces significant risks including policy changes in the pharmaceutical industry, reliance on a single leading product, and raw material procurement risks[72][73]. - The leading product, Si Mo Tang oral solution, accounts for nearly 50% of the company's revenue, indicating a high dependency on this product[72]. - The company plans to enhance product quality control and safety training to mitigate risks associated with production and environmental standards[74]. - The company aims to optimize product structure and expand market reach to maintain competitive advantages and reduce reliance on single products[74]. Corporate Governance - The company has not encountered any major changes in the feasibility of the committed investment projects[62]. - The company has made commitments regarding share transfer limitations, stating that shareholders will not transfer more than 25% of their total shares annually during their tenure[80]. - The company has committed to ensuring the legality and fairness of related party transactions, protecting the interests of minority shareholders[81]. - The company has not faced any media scrutiny during the reporting period[84]. Future Outlook - The company plans to continue focusing on market expansion and new product development to enhance future growth prospects[143]. - The company is actively exploring potential mergers and acquisitions to strengthen its market position[168]. - The company has set a performance guidance for the next quarter, aiming for a revenue growth of approximately 10%[160].

Financial Performance - The company's operating revenue for 2019 was ¥887,490,963.28, a decrease of 3.74% compared to ¥921,949,823.75 in 2018[16] - The net profit attributable to shareholders of the listed company was ¥162,377,707.21, an increase of 10.06% from ¥147,536,835.11 in the previous year[16] - The net cash flow from operating activities decreased by 25.19% to ¥167,788,107.51 from ¥224,290,282.23 in 2018[16] - Basic earnings per share increased to ¥0.3227, up 10.06% from ¥0.2932 in 2018[16] - Total assets at the end of 2019 were ¥1,882,905,804.71, representing a 4.70% increase from ¥1,798,360,607.85 at the end of 2018[17] - The net assets attributable to shareholders of the listed company rose by 12.22% to ¥1,529,977,688.84 from ¥1,363,344,314.12 in 2018[17] - The company reported a quarterly revenue of ¥266,317,591.14 in Q4 2019, the highest among the four quarters[21] - The company’s weighted average return on equity was 11.24%, slightly down from 11.41% in 2018[16] - The net profit after deducting non-recurring gains and losses was ¥154,338,124.68, an increase of 10.38% from ¥139,819,750.12 in 2018[16] - The company achieved a total profit of CNY 188,784,963.71 for the year 2019, with a net profit attributable to shareholders of CNY 162,377,707.21[98] Cash Flow and Investments - Cash and cash equivalents increased by 33.89 million yuan, a growth of 40.98% from the previous year[33] - The company’s cash flow from operating activities decreased by 25.19% to CNY -56.50 million, mainly due to a reduction in cash received from sales[46] - The company’s cash and cash equivalents increased significantly due to a reduction in bank loan repayments, with financing cash flow net increase of 19.90%[47] - The company reported a significant increase in investment activity cash inflow by 4,651.33% to ¥20,474,209.66, while cash outflow decreased by 40.73% to ¥75,710,585.59[66] - The total amount of long-term equity investments rose to ¥578,687,218, representing 30.73% of total assets, an increase of 1.01% from the previous year[70] Research and Development - Research and development expenses totaled CNY 33.62 million, with five products undergoing consistency evaluation, including sodium bicarbonate tablets which passed the evaluation in March 2019[42] - The company’s research and development expenses were impacted by the decision to capitalize previously incurred development costs[72] - The number of R&D personnel decreased by 22.55% to 158, while the proportion of R&D personnel in total staff decreased slightly to 10.12%[64] Market and Product Strategy - The company is engaged in the pharmaceutical manufacturing industry, focusing on the R&D, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations[26] - Key products include traditional Chinese medicine formulations such as Si Mo Decoction Oral Liquid and Ginkgo Leaf Capsules, which target various health issues[26][27] - The company is gradually expanding into the health and wellness sectors, indicating a strategic shift towards broader market opportunities[26] - The company plans to continue expanding into the health and medical care sectors, leveraging its diversified product portfolio[35] - The marketing strategy includes five categories: hospital promotion, grassroots promotion, chain promotion, commercial promotion, and controlled marketing[36] Corporate Governance and Compliance - The company has established a robust internal control system to protect the rights of shareholders and creditors, ensuring equal treatment for all shareholders, especially minority investors[129] - The company maintains a commitment to corporate governance and transparency through its independent directors and supervisory board[164] - The company has implemented a robust internal audit system to supervise daily operations and major related transactions[179] - The company emphasizes transparency and timely information disclosure, ensuring all investors are treated equally[178] Shareholder Information - The proposed cash dividend for 2019 is CNY 0.75 per share, amounting to a total distribution of CNY 37,740,000, which represents 23.24% of the net profit[94][96] - The company plans to maintain a cash dividend policy that ensures at least 30% of the average distributable profit over the last three years is distributed to shareholders[98] - The company has a total of 503,200,000 shares outstanding as of December 31, 2019, following a capital increase from retained earnings in 2018[94][98] - The largest shareholder, Xinjiang Hansen Equity Investment Management Co., Ltd., holds 40.14% of the shares, totaling 201,976,189 shares[146] Risk Management - The company faces risks related to policy changes in the pharmaceutical industry, reliance on a single product, and potential raw material supply shortages[86] - The company will strengthen its internal control systems and governance to mitigate risks and ensure compliance with industry regulations[85] Social Responsibility - The company actively engages in social responsibility initiatives, contributing to local economic development and participating in community welfare activities[131] - The company is committed to environmental protection and has improved its management level to meet industry standards, confirming it is not listed as a key pollutant unit[131][133]